红星资本局5月20日消息,5月19日,“猴茅”昭衍新药(603127.SH;06127.HK)召开2026年第一季度业绩说明会,就投资者关心的业绩表现、订单情况、实验猴价格趋势等问题进行了回应。 昭衍新药2026年一季报显示,一季度实现营业总收入3.16亿元,同比增长10.02%;归母净利润2.38亿元,同比增长479.67%;扣非净利润2.17亿元,同比增长747.11%;经营活动产生的...
Source Link红星资本局5月20日消息,5月19日,“猴茅”昭衍新药(603127.SH;06127.HK)召开2026年第一季度业绩说明会,就投资者关心的业绩表现、订单情况、实验猴价格趋势等问题进行了回应。 昭衍新药2026年一季报显示,一季度实现营业总收入3.16亿元,同比增长10.02%;归母净利润2.38亿元,同比增长479.67%;扣非净利润2.17亿元,同比增长747.11%;经营活动产生的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.